Rapport Therapeutics Inc
NASDAQ:RAPP
Rapport Therapeutics Inc
NASDAQ:RAPP
Price:
34.17
USD
-0.15%
Market Closed
Market Cap:
$1.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Rapport Therapeutics Inc
NASDAQ:RAPP
|
US |
|
A
|
Arecor Therapeutics PLC
LSE:AREC
|
UK |
|
APA Corp (US)
NASDAQ:APA
|
US |
|
Silvercorp Metals Inc
TSX:SVM
|
CA |
Income Statement
Earnings Waterfall
Rapport Therapeutics Inc
Rapport Therapeutics Inc
Income Statement
Rapport Therapeutics Inc
Rapport Therapeutics Inc
Currency: USD
| Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||
| Operating Expenses |
(74)
|
(96)
|
(83)
|
(93)
|
(102)
|
(110)
|
(125)
|
|
| Selling, General & Administrative |
(18)
|
(24)
|
(22)
|
(25)
|
(27)
|
(28)
|
(30)
|
|
| Research & Development |
(56)
|
(72)
|
(61)
|
(68)
|
(75)
|
(82)
|
(95)
|
|
| Operating Income |
(74)
N/A
|
(96)
-29%
|
(83)
+13%
|
(93)
-12%
|
(102)
-9%
|
(110)
-8%
|
(125)
-14%
|
|
| Pre-Tax Income | ||||||||
| Interest Income Expense |
7
|
11
|
12
|
13
|
13
|
12
|
14
|
|
| Total Other Income |
(9)
|
(9)
|
(7)
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(76)
N/A
|
(93)
-23%
|
(78)
+16%
|
(80)
-2%
|
(88)
-11%
|
(98)
-11%
|
(111)
-14%
|
|
| Net Income | ||||||||
| Tax Provision |
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(76)
|
(93)
|
(78)
|
(80)
|
(88)
|
(98)
|
(111)
|
|
| Net Income (Common) |
(76)
N/A
|
(93)
-23%
|
(78)
+16%
|
(80)
-2%
|
(88)
-11%
|
(98)
-11%
|
(111)
-14%
|
|
| EPS (Diluted) |
-2.04
N/A
|
-2.67
-31%
|
-3.78
-42%
|
-2.25
+40%
|
-2.51
-12%
|
-2.57
-2%
|
-2.86
-11%
|
|
Switch to:
Switch to:
See Also
Discover More
